GlassScriptPhysician profile
Eric R Uyguanco
NPI 1326219569
$11,874.58
in general payments reported to CMS, 2019-2025
20 companies · $960 in 2025
The $960 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,059 · 2020: $582 · 2021: $900 · 2022: $1,644 · 2023: $1,354 · 2024: $1,375 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,689.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,137.54 | 2019 | |
| Abbott Laboratories | $3,342.41 | 2019-2025 | Aveir, Jot Dx, Cardiomems |
| Boston Scientific Corporation | $652.93 | 2019-2025 | Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $626.40 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $562.87 | 2022-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $483.72 | 2019-2023 | |
| Medtronic, INC. | $379.98 | 2021-2024 | Micra, Attain Command + Surevalve, Crome Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $333.49 | 2021-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $303.87 | 2022-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $268.44 | 2019-2023 | Xarelto |
| Pfizer INC. | $182.57 | 2019-2025 | |
| Abiomed | $145.58 | 2024 | Impella |
| Biotronik INC. | $133.49 | 2019 | |
| Astellas Pharma US INC | $101.37 | 2019-2021 | |
| Biosense Webster, INC. | $58.33 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $58.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.21 | 2021 | |
| Daiichi Sankyo INC. | $29.05 | 2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $28.58 | 2024 | Amvuttra |
| Chiesi USA, INC. | $15.69 | 2023 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Uyguanco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.